title: Boosting a Drug's Market Share Can Cross a Dangerous Line.
abstract: Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.
authors.forename: Thomas
authors.initials: T
authors.lastname: Reinke
mesh_terms: D003132:Commerce; D004345:Drug Industry; D006801:Humans